Matrine
Based on 19 publication(s) in Google Scholar
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.0%
- CAS. Nr.: 519-02-8
- Formel: C15H24N2O
- Molecular Weight:248.36
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Matrine
More- Phytomedicine. 2025 May:140:156484. [Abstract]
- Arch Toxicol. 2026 Jan 14. [Abstract]
- Chin Med. 2022 Feb 18;17(1):23. [Abstract]
- J Ethnopharmacol. 2025 Jun 26:350:120054. [Abstract]
- J Ethnopharmacol. 2022 Mar 1:285:114796. [Abstract]
- Drug Des Devel Ther. 2023 Sep 11:17:2787-2804. [Abstract]
- Eur J Pharmacol. 2025 Apr 15:993:177385. [Abstract]
- J Cell Mol Med. 2025 May;29(10):e70617. [Abstract]
- J Cell Mol Med. 2022 Jul;26(13):3702-3715. [Abstract]
- J Biochem Mol Toxicol. 2023 Oct;37(10):e23436. [Abstract]
- Chem Biol Drug Des. 2023 Dec;102(6):1469-1477. [Abstract]
- Mutagenesis. 2024 Feb 8;39(1):32-42. [Abstract]
- Am J Cancer Res. 2021 Sep 15;11(9):4308-4328. [Abstract]
- Clin Exp Pharmacol Physiol. 2025 Nov;52(11):e70072. [Abstract]
- Exp Ther Med. 2019 May;17(5):3775-3780. [Abstract]
- Xenobiotica. 2026 May;56(5):443-452. [Abstract]
- Research Square Preprint. 2024 Mar 25.
- Bioengineered. 2022 Feb;13(2):2851-2865. [Abstract]
- Biomed Pharmacother. 2020 Aug:128:110327. [Abstract]
-
IF
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
IHC
-
WB
Alle Opioid Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
κ Opioid Receptor/KOR |
μ Opioid Receptor/MOR |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
1.11 mg/mL
Compound: 1
|
Antiproliferative activity against mouse 4T1 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse 4T1 cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| 5637 | IC50 |
4.48 mM
Compound: 1
|
Antiproliferative activity against human 5637 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human 5637 cells after 48 hrs by CCK8 assay
|
[PMID: 30359819] |
| A549 | IC50 |
>40 μM
Compound: 3
|
Antiproliferative activity against human A549 cells after 3 days by SRB assay
Antiproliferative activity against human A549 cells after 3 days by SRB assay
|
[PMID: 26865176] |
| A549 | IC50 |
>50 μM
Compound: Matrine
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
|
[PMID: 25959813] |
| A549 | IC50 |
3.15 μM
Compound: Matrine
|
Antiproliferative activity against human A549 cells by CCK8 assay
Antiproliferative activity against human A549 cells by CCK8 assay
|
[PMID: 34922028] |
| A549 | IC50 |
3923 μM
Compound: Matrine
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 27481558] |
| A549 | IC50 |
5725 μM
Compound: Matrine
|
Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs MTT assay
Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs MTT assay
|
[PMID: 29395978] |
| A549 | IC50 |
5885 μM
Compound: Matrine
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38554475] |
| A549 | IC50 |
9.7 μg/mL
Compound: 1
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 22578453] |
| B16-F10 | IC50 |
17 μg/mL
Compound: 1
|
Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay
|
[PMID: 22578453] |
| Bel-7402 | IC50 |
>50 μM
Compound: Matrine
|
Antiproliferative activity against human Bel7402 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human Bel7402 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
|
[PMID: 25959813] |
| Bel-7402 | IC50 |
2057 μM
Compound: Matrine
|
Antiproliferative activity against human Bel7402 cells after 48 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 48 hrs by MTT assay
|
[PMID: 27481558] |
| Bel-7402 | IC50 |
3.22 mM
Compound: 1
|
Antiproliferative activity against human Bel7402 cells after 48 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| BXPC-3 | IC50 |
2.94 mM
Compound: 1
|
Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
|
[PMID: 30359819] |
| C-33-A | IC50 |
5.92 mM
Compound: 1
|
Antiproliferative activity against human C33A cells after 48 hrs by CCK8 assay
Antiproliferative activity against human C33A cells after 48 hrs by CCK8 assay
|
[PMID: 30359819] |
| CAL-27 | IC50 |
21 μg/mL
Compound: Matr
|
Antiproliferative activity against human CAL-27 cells assessed as cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human CAL-27 cells assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 34463097] |
| Calu-3 | IC50 |
7.54 μM
Compound: Matrine
|
Antiproliferative activity against human Calu-3 cells by CCK8 assay
Antiproliferative activity against human Calu-3 cells by CCK8 assay
|
[PMID: 34922028] |
| Ca-Ski | IC50 |
5.8 mM
Compound: 1
|
Antiproliferative activity against human CaSki cells after 48 hrs by CCK8 assay
Antiproliferative activity against human CaSki cells after 48 hrs by CCK8 assay
|
[PMID: 30359819] |
| CCRF-CEM | IC50 |
11.68 mM
Compound: 1
|
Antiproliferative activity against human CCRF-CEM cells after 24 hrs by WST1 assay
Antiproliferative activity against human CCRF-CEM cells after 24 hrs by WST1 assay
|
[PMID: 30359819] |
| CCRF-CEM | IC50 |
9.63 mM
Compound: 1
|
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by WST1 assay
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by WST1 assay
|
[PMID: 30359819] |
| CCRF-CEM | IC50 |
9.67 mM
Compound: 1
|
Antiproliferative activity against human CCRF-CEM cells after 48 hrs by WST1 assay
Antiproliferative activity against human CCRF-CEM cells after 48 hrs by WST1 assay
|
[PMID: 30359819] |
| CNE-2 | IC50 |
5278 μM
Compound: Matrine
|
Anticancer activity against human CNE2 cells assessed as reduction in cell viability incubated for 48 hrs MTT assay
Anticancer activity against human CNE2 cells assessed as reduction in cell viability incubated for 48 hrs MTT assay
|
[PMID: 29395978] |
| DLD-1 | IC50 |
6.32 mM
Compound: 1
|
Growth inhibition of human DLD1 cells after 24 hrs by MTT assay
Growth inhibition of human DLD1 cells after 24 hrs by MTT assay
|
[PMID: 30359819] |
| EJ | IC50 |
5.09 mM
Compound: 1
|
Antiproliferative activity against human EJ cells after 48 hrs by CCK8 assay
Antiproliferative activity against human EJ cells after 48 hrs by CCK8 assay
|
[PMID: 30359819] |
| HEK-293T | IC50 |
>4220 μM
Compound: Matrine
|
Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37084600] |
| HeLa | IC50 |
>50 μM
Compound: Matrine
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
|
[PMID: 25959813] |
| HeLa | IC50 |
4332 μM
Compound: Matrine
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31928863] |
| HeLa | IC50 |
6748 μM
Compound: Matrine
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38554475] |
| HeLa | IC50 |
8.12 μM
Compound: Matrine
|
Antiproliferative activity against human HeLa cells by CCK8 assay
Antiproliferative activity against human HeLa cells by CCK8 assay
|
[PMID: 34922028] |
| HepG2 | IC50 |
>4900 μM
Compound: Matrine
|
Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 37084600] |
| HepG2 | IC50 |
3.22 mM
Compound: 1
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| HepG2 | IC50 |
4359 μM
Compound: Matrine
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38554475] |
| HepG2 | IC50 |
4509 μM
Compound: Matrine
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31928863] |
| HepG2 | IC50 |
8069 μM
Compound: 1
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
[PMID: 30359819] |
| HGC-27 | IC50 |
4180 μM
Compound: Matrine
|
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38554475] |
| HK-2 | IC50 |
4.71 mM
Compound: 1
|
Antiproliferative activity against human HK2 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human HK2 cells after 48 hrs by CCK8 assay
|
[PMID: 30359819] |
| HL-60 | IC50 |
3.66 μM
Compound: 1
|
Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
|
[PMID: 30359819] |
| HOS-TE85 | IC50 |
3.1 mM
Compound: 1
|
Growth inhibition of human MNNG-HOS cells after 48 hrs by MTT assay
Growth inhibition of human MNNG-HOS cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| HSC-T6 | IC50 |
128 μM
Compound: MT
|
Antiproliferative activity against rat HSC-T6 cells
Antiproliferative activity against rat HSC-T6 cells
|
[PMID: 31884408] |
| HT-29 | IC50 |
28.6 μM
Compound: 1
|
Antiproliferative activity against human HT-29 cells by MTT assay
Antiproliferative activity against human HT-29 cells by MTT assay
|
[PMID: 30359819] |
| HT-29 | IC50 |
6.32 mM
Compound: 1
|
Growth inhibition of human HT-29 cells after 24 hrs by MTT assay
Growth inhibition of human HT-29 cells after 24 hrs by MTT assay
|
[PMID: 30359819] |
| K562 | IC50 |
1.77 mM
Compound: 1
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 30359819] |
| KB | IC50 |
>40 μM
Compound: 3
|
Antiproliferative activity against human KB cells after 3 days by SRB assay
Antiproliferative activity against human KB cells after 3 days by SRB assay
|
[PMID: 26865176] |
| KYSE-150 cell line | IC50 |
7.82 mM
Compound: 1
|
Antiproliferative activity against human KYSE-150 cells after 24 hrs by MTT assay
Antiproliferative activity against human KYSE-150 cells after 24 hrs by MTT assay
|
[PMID: 30359819] |
| L02 | IC50 |
23.59 μM
Compound: Matrine
|
Cytotoxicity against human L02 cells by CCK8 assay
Cytotoxicity against human L02 cells by CCK8 assay
|
[PMID: 34922028] |
| LoVo | IC50 |
1.66 mM
Compound: 1
|
Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
|
[PMID: 30359819] |
| LoVo | IC50 |
2.97 mM
Compound: 1
|
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| LoVo | IC50 |
4.63 mM
Compound: 1
|
Antiproliferative activity against human LoVo cells after 24 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 24 hrs by MTT assay
|
[PMID: 30359819] |
| M21 | IC50 |
3.1 mM
Compound: 1
|
Growth inhibition of human M21 cells after 48 hrs by MTT assay
Growth inhibition of human M21 cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| MCF7 | IC50 |
>50 μM
Compound: Matrine
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
|
[PMID: 25959813] |
| MCF7 | IC50 |
0.721 mg/mL
Compound: 1
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| MCF7 | IC50 |
2497 μM
Compound: Matrine
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 27481558] |
| MCF7 | IC50 |
7.26 μM
Compound: Matrine
|
Antiproliferative activity against human MCF7 cells by CCK8 assay
Antiproliferative activity against human MCF7 cells by CCK8 assay
|
[PMID: 34922028] |
| MDA-MB-231 | IC50 |
>40 μM
Compound: 3
|
Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay
|
[PMID: 26865176] |
| MDA-MB-231 | IC50 |
4.15 μM
Compound: Matrine
|
Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay
|
[PMID: 34922028] |
| MDA-MB-231 | IC50 |
5372 μM
Compound: Matrine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31928863] |
| MDCK | CC50 |
>80 μM
Compound: 8
|
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
|
[PMID: 25147619] |
| MDCK | EC50 |
>80 μM
Compound: 8
|
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay
|
[PMID: 25147619] |
| MG-63 | IC50 |
7.05 mM
Compound: 1
|
Growth inhibition of human MG63 cells after 48 hrs by MTT assay
Growth inhibition of human MG63 cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| MM1.S | IC50 |
4.95 mM
Compound: 1
|
Growth inhibition of human MM1S cells after 24 hrs
Growth inhibition of human MM1S cells after 24 hrs
|
[PMID: 30359819] |
| MRC5 | IC50 |
878 μM
Compound: MT
|
Anti-fibrotic activity in human MRC5 cells assessed as inhibition of TGF-beta1 induced total collagen deposition
Anti-fibrotic activity in human MRC5 cells assessed as inhibition of TGF-beta1 induced total collagen deposition
|
[PMID: 31884408] |
| NB-4 | IC50 |
2.66 μM
Compound: 1
|
Antiproliferative activity against human NB4 cells after 24 hrs by MTT assay
Antiproliferative activity against human NB4 cells after 24 hrs by MTT assay
|
[PMID: 30359819] |
| NCI-H1650 | IC50 |
6.27 μM
Compound: Matrine
|
Antiproliferative activity against human H1650 cells by CCK8 assay
Antiproliferative activity against human H1650 cells by CCK8 assay
|
[PMID: 34922028] |
| NCI-H460 | IC50 |
7.03 μM
Compound: Matrine
|
Antiproliferative activity against human H460 cells by CCK8 assay
Antiproliferative activity against human H460 cells by CCK8 assay
|
[PMID: 34922028] |
| NIH3T3 | IC50 |
>8.06 mM
Compound: 1
|
Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay
|
[PMID: 30359819] |
| PANC-1 | IC50 |
28.6 μM
Compound: 1
|
Antiproliferative activity against human PANC1 cells by MTT assay
Antiproliferative activity against human PANC1 cells by MTT assay
|
[PMID: 30359819] |
| PANC-1 | IC50 |
3.66 mM
Compound: 1
|
Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay
Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 30359819] |
| RAW264.7 | IC50 |
>200 μM
Compound: Matrine
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production after 6 hrs by ELISA
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production after 6 hrs by ELISA
|
[PMID: 21036613] |
| RPMI-8226 | IC50 |
1.64 g/L
Compound: 1
|
Antiproliferative activity against human RPMI8226 cells after 48 hrs by MTT assay
Antiproliferative activity against human RPMI8226 cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| RPMI-8226 | IC50 |
2.25 g/L
Compound: 1
|
Antiproliferative activity against human RPMI8226 cells after 24 hrs by MTT assay
Antiproliferative activity against human RPMI8226 cells after 24 hrs by MTT assay
|
[PMID: 30359819] |
| RPMI-8226 | IC50 |
4.35 mM
Compound: 1
|
Growth inhibition of human RPMI8226 cells after 24 hrs
Growth inhibition of human RPMI8226 cells after 24 hrs
|
[PMID: 30359819] |
| SAOS-2 | IC50 |
4.27 mM
Compound: 1
|
Growth inhibition of human Saos2 cells after 48 hrs by MTT assay
Growth inhibition of human Saos2 cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| SCC-9 | IC50 |
>100 μg/mL
Compound: Matr
|
Antiproliferative activity against human SCC-9 cells assessed as cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human SCC-9 cells assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 34463097] |
| SGC-7901 | IC50 |
1380 μM
Compound: Matrine
|
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
|
[PMID: 27481558] |
| SiHa | IC50 |
5.76 mM
Compound: 1
|
Antiproliferative activity against human SiHa cells after 48 hrs by CCK8 assay
Antiproliferative activity against human SiHa cells after 48 hrs by CCK8 assay
|
[PMID: 30359819] |
| SMMC-7721 | IC50 |
6591 μM
Compound: Matrine
|
Anticancer activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs MTT assay
Anticancer activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs MTT assay
|
[PMID: 29395978] |
| T-24 | IC50 |
4.6 mM
Compound: 1
|
Antiproliferative activity against human T24 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human T24 cells after 48 hrs by CCK8 assay
|
[PMID: 30359819] |
| U-266 | IC50 |
1.58 g/L
Compound: 1
|
Antiproliferative activity against human U266 cells after 48 hrs by MTT assay
Antiproliferative activity against human U266 cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| U-266 | IC50 |
2.18 g/L
Compound: 1
|
Antiproliferative activity against human U266 cells after 24 hrs by MTT assay
Antiproliferative activity against human U266 cells after 24 hrs by MTT assay
|
[PMID: 30359819] |
| U2OS | IC50 |
7.25 mM
Compound: 1
|
Growth inhibition of human U2OS cells after 48 hrs by MTT assay
Growth inhibition of human U2OS cells after 48 hrs by MTT assay
|
[PMID: 30359819] |
| U-937 | IC50 |
2.37 μM
Compound: 1
|
Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
Antiproliferative activity against human U937 cells after 24 hrs by MTT assay
|
[PMID: 30359819] |
Matrine (0-1.5 mg/mL, 24-72 h) inhibits the growth of A549 and SMMC-7721 cells[1]. Matrine (25 μg/mL, 6 h) suppresses migration of A549 cells[1]. Matrine (0-1 mg/mL, 48 h) induces apoptosis by reducing the Bcl-2/Bax protein ratios in A549 and SMMC-7721 cells[1]. Matrine (0-1 mg/mL, 48 h) inhibits miR-182-5p expression and induces the apoptosis of PTC cells[2]. Matrine (10 μM, 48 h) inhibits cisplatin-induced oxidative injury and inflammation in HK2 cells by reducing ROS level and pro-inflammatory cytokines including IL-1β, IL-6 and TNF-α[4]. Matrine (10 μM, 48 h) reverses mitochondrial function in cisplatin-induced HK2 cells by activating the SIRT3/OPA1 pathway[4]. Matrine (0-20 nM, 12 h) promotes HepG2 cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549, SMMC-7721 cells
-
Concentration:0-500 μg/mL for A549 cells, 0-1.5 mg/mL for SMMC-7721 cells
-
Incubation Time:24-72 h
-
Result:Inhibited the growth of A549 and SMMC-7721 cells.
-
Cell Line:A549, SMMC-7721 cells
-
Concentration:100-250 μg/mL for A549 cells, 0.5-1 mg/mL for SMMC-7721 cells
-
Incubation Time:24 h
-
Result:Down-regulated the expression of anti-apoptotic protein (Bcl-2) and up-regulated the level of pro-apoptotic protein (bax).
-
Cell Line:HK2 cells
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Increased SIRT3 expression reduced under cisplatin stimuli.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Xenograft male C57BL/6mice model (LLC cells)[3]
-
Dosage:40 and 80 mg/kg for 16 consecutive days
-
Administration:Intragastric administration
-
Result:Inhibited tumors growth. Decreased the ratio of CD206+/F4/80+, promoted the expression of CD4+ and CD8+ T cells, and inhibited the expression of Th2 in tumor and spleen tissues.
-
Animal Model:Cisplatin-induced acute kidney injury (AKI) mice model[4]
-
Dosage:5 mg/kg daily for 4 days
-
Administration:Intraperitoneal injections
-
Result:Attenuated tubular injury observed in AKI mice, including renal tubular necrosis,formation of tubular casts, cytoplasmic vacuoles and renal infiltrationof inflammatory cells in mice. Decreased serum levels of TNF-a and IL-6 and the phosphorylation of NF-κB, activated SIRT3/OPA1 axis and improved mitochondrial function.
Chemical Information
-
CAS. Nr. 519-02-8
-
Appearance Solid
-
Molecular Weight 248.36
-
Formel C15H24N2O
-
Color White to off-white
-
SMILES
O=C1CCC[C@]2([H])[C@@]3([H])CCCN4[C@@]3([H])[C@](CCC4)([H])CN21
-
Synonyms
Matridin-15-one; Vegard; α-Matrine
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (19)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
Arch Toxicol
How the methodology determines the outcome of the in vitro micronucleus assay (OECD TG 487): a comparison of the MicroFlow and the microscopic evaluation approach highlights the impact of cytotoxicity/cytostasis metrics in V79 cells for matrine. [Abstract]2026 Jan 14. PMID: 41535592 -
Chin Med
Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence. [Abstract]2022 Feb 18;17(1):23. PMID: 35180857
Matrine purchased from MedChemExpress. Usage Cited in: Chin Med. 2022 Feb 18;17(1):23. [Abstract]
Matrine (6.25, 12.5, 25, 50, 100, and 200 µM; 24 h) inhibited the growth of HSCs.
Matrine purchased from MedChemExpress. Usage Cited in: Chin Med. 2022 Feb 18;17(1):23. [Abstract]
Matrine (50 µM, 24 h) inhibited the mRNA expression of α-SMA and collagen I in TGFβ1-activated HSC-T6 cells.
-
J Ethnopharmacol
Compound kushen injection inhibits breast cancer lung metastasis through regulating MTSS1/ARPC3/F-actin. [Abstract]2025 Jun 26:350:120054. PMID: 40446975
Matrine purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2025 Jun 26:350:120054. [Abstract]
Immunofluorescence imaging of F-actin using phalloidin staining in 4T1 and MDA-MB-231 cells treated with MT (50 μM, 24 h). Phalloidin was diluted in PBS containing 5% bovine serum albumin and incubated at room temperature for 1 h in the dark.
-
J Ethnopharmacol
Isoxanthohumol, a component of Sophora flavescens, promotes the activation of the NLRP3 inflammasome and induces idiosyncratic hepatotoxicity. [Abstract]2022 Mar 1:285:114796. PMID: 34740771 -
Drug Des Devel Ther
Pharmacological Activity of Matrine in Inhibiting Colon Cancer Cells VM Formation, Proliferation, and Invasion by Downregulating Claudin-9 Mediated EMT Process and MAPK Signaling Pathway. [Abstract]2023 Sep 11:17:2787-2804. PMID: 37719361 -
Eur J Pharmacol
Matrine alleviates Staphylococcus aureus-induced acute lung injury in mice by inhibiting MLKL and NLRP3-mediated inflammatory activity. [Abstract]2025 Apr 15:993:177385. PMID: 39956265 -
J Cell Mol Med
Matrine Inhibits the Wnt3a/β-Catenin Signalling to Attenuate Pressure Overload-Induced Atrial Remodelling and Vulnerability to Atrial Fibrillation. [Abstract]2025 May;29(10):e70617. PMID: 40407710 -
J Cell Mol Med
Matrine alleviates cisplatin-induced acute kidney injury by inhibiting mitochondrial dysfunction and inflammation via SIRT3/OPA1 pathway. [Abstract]2022 Jul;26(13):3702-3715. PMID: 35650472 -
J Biochem Mol Toxicol
Matrine suppresses liver cancer progression and the Warburg effect by regulating the circROBO1/miR-130a-5p/ROBO1 axis. [Abstract]2023 Oct;37(10):e23436. PMID: 37376914 -
Chem Biol Drug Des
Matrine exerts an anti-tumor effect via regulating HN1 in triple breast cancer both in vitro and in vivo. [Abstract]2023 Dec;102(6):1469-1477. PMID: 37674344 -
Mutagenesis
Matrine and Oxymatrine: Evaluating the gene mutation potential using in silico tools and the bacterial reverse mutation assay (Ames test). [Abstract]2024 Feb 8;39(1):32-42. PMID: 37877816 -
Am J Cancer Res
Matrine suppresses lung cancer metastasis via targeting M2-like tumour-associated-macrophages polarization. [Abstract]2021 Sep 15;11(9):4308-4328. PMID: 34659889 -
Clin Exp Pharmacol Physiol
Combination of Tanshinone IIA and Matrine Alleviates Lipopolysaccharide-Induced Acute Lung Injury by Supressing Ferroptosis via Nrf2/HO-1 Pathway Activation. [Abstract]2025 Nov;52(11):e70072. PMID: 41063422 -
Exp Ther Med
Matrine inhibits the proliferation of pituitary tumor cells by decreasing Foxo3a phosphorylation and promoting Foxo3a nuclear localization. [Abstract]2019 May;17(5):3775-3780. PMID: 30988763
Matrine purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2019 May;17(5):3775-3780. [Abstract]
Matrine promotes the nuclear Foxo3a localization and inhibits the levels of cytoplasmic Foxo3a. RC‑4B/C cells are treated with increasing concentrations of matrine for 24 h. The levels of Foxo3 are determined by western blotting analysis. β‑tubulin is used as cytoplasmic marker and lamin B1 is used as nuclear marker in RC‑4B/C cells. The gray values of Foxo3a is shown in histogram in different concentrations of matrine‑treated pituitary cancer cells.
Matrine purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2019 May;17(5):3775-3780. [Abstract]
Matrine increases the expression of pro‑apoptotic proteins in RC‑4B/C cells. RC‑4B/C cells are treated with 0.1, 0.5 and 2.5 mg/ml of matrine for 24 h and the expression of Bim, Bax and Bcl‑2 is determined by western blotting analysis. RC‑4B/C cells treated with 0.1% DMSO are used as negative controls. β‑actin is used as internal reference gene in pituitary cancer cells.
-
Xenobiotica
Synergistic therapeutic effect and mechanism of Cryptotanshinone combined with Matrine on ovarian cancer. [Abstract]2026 May;56(5):443-452. PMID: 42091250 -
-
Bioengineered
Novel protein kinase C phosphorylated kinase inhibitor-matrine suppresses replication of hepatitis B virus via modulating the mitogen-activated protein kinase signal. [Abstract]2022 Feb;13(2):2851-2865. PMID: 35037840 -
Biomed Pharmacother
Matrine induces papillary thyroid cancer cell apoptosis in vitro and suppresses tumor growth in vivo by downregulating miR-182-5p. [Abstract]2020 Aug:128:110327. PMID: 32505823
Matrine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Aug:128:110327. [Abstract]
Overexpression of miR-182-5p abolishes the Matrine-induced increase in caspase3 expression and decrease in Bcl-2 expression in vivo. Tumor sections are subjected to IHC staining using an antibody specific for caspase3 and Bcl-2.
Lösungsmittel & Löslichkeit
DMSO : ≥ 50 mg/mL (201.32 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 20 mg/mL (80.53 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 37.5 mg/mL (150.99 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Reinheit & Dokumentation
-
Data Sheet (289 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Ying Zhang, et al. Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology. 2009 Apr;59(3):191-200. [Content Brief]
[2]. Songbo Fu, et al. Matrine induces papillary thyroid cancer cell apoptosis in vitro and suppresses tumor growth in vivo by downregulating miR-182-5p. Biomed Pharmacother. 2020 Aug;128:110327. [Content Brief]
[3]. Bei Zhao, et al. Matrine suppresses lung cancer metastasis via targeting M2-like tumour-associated-macrophages polarization. Am J Cancer Res. 2021 Sep 15;11(9):4308-4328. [Content Brief]
[5]. Runjie Wei, et al. Matrine promotes liver cancer cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways. Cell Stress Chaperones. 2018 Nov;23(6):1295-1309. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.0264 mL | 20.1321 mL | 40.2641 mL | 100.6603 mL |
| 5 mM | 0.8053 mL | 4.0264 mL | 8.0528 mL | 20.1321 mL | |
| 10 mM | 0.4026 mL | 2.0132 mL | 4.0264 mL | 10.0660 mL | |
| 15 mM | 0.2684 mL | 1.3421 mL | 2.6843 mL | 6.7107 mL | |
| 20 mM | 0.2013 mL | 1.0066 mL | 2.0132 mL | 5.0330 mL | |
| 25 mM | 0.1611 mL | 0.8053 mL | 1.6106 mL | 4.0264 mL | |
| 30 mM | 0.1342 mL | 0.6711 mL | 1.3421 mL | 3.3553 mL | |
| 40 mM | 0.1007 mL | 0.5033 mL | 1.0066 mL | 2.5165 mL | |
| 50 mM | 0.0805 mL | 0.4026 mL | 0.8053 mL | 2.0132 mL | |
| 60 mM | 0.0671 mL | 0.3355 mL | 0.6711 mL | 1.6777 mL | |
| 80 mM | 0.0503 mL | 0.2517 mL | 0.5033 mL | 1.2583 mL | |
| DMSO | 100 mM | 0.0403 mL | 0.2013 mL | 0.4026 mL | 1.0066 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.